Results 171 to 180 of about 26,394 (258)

Novel bispecific T-cell engagers overcoming acquired EGFR resistance. [PDF]

MAbs
Kühl L, Löffler AK, Seifert O, Michler D, Kuhlmann M, Russo G, Kuhn P, Nowack H, Frenzel A, Schirrmann T, Olayioye MA, Kontermann RE.   +11 more
europepmc   +1 more source

Intelligent design of artificial biocatalyst for biomedical diseases

Journal of Intelligent Medicine, Volume 3, Issue 3, Page 220-249, September 2026.
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang, Nan Song, Huanhuan Qiao, Si Sun   +3 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

Hemasphere
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.   +18 more
europepmc   +1 more source

Improving Proteolysis‐Targeting Chimera Delivery by Targeting Key Biomarkers in Tumor Endocytosis Pathways

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
The image illustrates how PROTACs utilize endocytosis, mediated by cell surface proteins, to overcome bioavailability limitations and enable efficient intracellular delivery. ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are promising therapeutic agents for targeted protein degradation via the ubiquitin‐proteasome system; however, their clinical ...
Huahua Chen, Jiayan Jiao, Huiling Yang, Tao He   +3 more
wiley   +1 more source

PD-L1/Lag3 Bispecific Immune Checkpoint Blocking Nanocage Exhibits Potent Antitumor Activity beyond Dual Blockade of PD-L1 and Lag3. [PDF]

Biomater Res
Lee SM, Kim M, Lee C, Lee M, Yoon HJ, Lee B, Park EJ, Kim S.   +7 more
europepmc   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV. [PDF]

Emerg Microbes Infect
Lu H, Li L, Zhang N, Liu Y, Liu B, Sun Y, Zhang J, Liu S, Luo J, Liao J, Lv K, Yue X, Xu M, Zhao J, Wu X, Chen X, Tao C, Guo Y, Zhang Z, Wang M, Chen YQ.   +20 more
europepmc   +1 more source

Abscopal Effect in Radiation Therapy: The Immune Mechanisms and Clinical Advances

MedComm, Volume 7, Issue 9, September 2026.
The schematic outlines the key events of the abscopal effect. (Ignition) Local radiotherapy (RT) induces the release of immunogenic signals from the tumor, leading to dendritic cell (DC) activation. (Orchestration) In the tumor‐draining lymph node (TDLN), DCs prime naive T cells into cytotoxic T lymphocytes (CTLs), a process modulated by regulatory T ...
Yihong Dong, Moran Chen, Xupeng Hou, Xiaoya Tang, Xiaoli Yu, Jing Liu   +5 more
wiley   +1 more source

Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges. [PDF]

Biomedicines
Rotte A, Sopjani M, Bhandaru M.
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source